

**LISTING OF CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

- 1-75. (Cancelled)
76. (Previously Presented) A method for treating a tumor, comprising administering indinavir at a daily dose of 1200 mg to a human subject having a tumor.
77. (Previously Presented) A method for blocking cell migration or invasion, comprising administering indinavir at a daily dose of 1200 mg to a human subject in need of said blocking.
78. (Previously Presented) The method of claim 77, wherein said blocking is of neoplastic cell migration or invasion.
79. (Previously Presented) The method of claim 76 or 77, wherein said human subject is not infected with HIV.
80. (Previously Presented) The method of claim 76 or 77, further comprising administering to said human subject nelfinavir.
81. (Previously Presented) The method of claim 76, wherein the tumor is Kaposi's sarcoma.
82. (Previously Presented) The method of claim 76, wherein the tumor is a benign tumor of soft tissue, cartilage, bone or blood.
83. (Previously Presented) The method of claim 76, wherein the tumor is a malignant tumor of soft tissue, cartilage, bone or blood.
84. (Previously Presented) The method of claim 76 or 77, further comprising administering to said human subject an anti-inflammatory, anti-angiogenic or anti-tumor drug.
85. (Previously Presented) The method of claim 76 or 77, wherein said administering of the indinavir is orally, intravenously, intramuscularly, subcutaneously, intradermally,

intraperitoneally, intrathecally, intrapleurally, intrauterine, transmucosally, rectally, vaginally, intralesionally or percutaneously.

86. (Previously Presented) The method of claim 76 or 77, wherein said administering of the indinavir is orally.